Pharmacological Basis for the Neurocognitive Effect of Atypical Antipsychotic Drugs

참고문헌 (84)

1. Heinrichs RW, "Neurocognitive deficit in schizophrenia: a quantitative review of the evidence", Neuropsychology, 12, pp.426~445 (1998)
2. Palmer BW, "What do we know about neuropsychological aspects of schizophrenia?", Neuropsychol Rev, 19, pp.365~384 (2009)
3. Dickinson D, "General and specific cognitive deficits in schizophrenia", Biol Psychiatry, 55, pp.826~833 (2004)
4. Saykin AJ, "Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia", Arch Gen Psychiatry, 51, pp.124~131 (1994)
5. Sitskoorn MM, "Memory profiles in parents of patients with schizophrenia", Psychiatry Res, 128, pp.27~37 (2004)
6. Green MF, "What are the functional consequences of neurocognitive deficits in schizophrenia?", Am J Psychiatry, 153, pp.321~330 (1996)
7. Velligan DI, "Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?", J Nerv Ment Dis, 188, pp.518~524 (2000)
8. Meltzer HY, "The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia", Schizophr Bull, 25, pp.233~255 (1999)
9. Keefe RS, "The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis", Schizophr Bull, 25, pp.201~222 (1999)
10. Harvey PD, "Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment", Am J Psychiatry, 158, pp.176~184 (2001)
11. Weiss EM, "The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia", Psychopharmacology (Berl), 162, pp.11~17 (2002)
12. Woodward ND, "A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia", Int J Neuropsychopharmacol, 8, pp.457~472 (2005)
13. Meltzer HY, "Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values", J Pharmacol Exp Ther, 251, pp.238~246 (1989)
14. Kuroki T, "Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis", Prog Brain Res, 172, pp.199~212 (2008)
15. Mishara AL, "A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book", Biol Psychiatry, 55, pp.1013~1022 (2004)
16. Woodward ND, "A metaanalysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects", Schizophr Res, 89, pp.211~224 (2007)
17. Harvey PD, "Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial", Am J Psychiatry, 162, pp.1888~1895 (2005)
18. Keefe RS, "HGDH Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia", Schizophr Res, 81, pp.1~15 (2006)
19. Keefe RS, "CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial", Arch Gen Psychiatry, 64, pp.633~647 (2007)
20. Davidson M, "Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)", Am J Psychiatry, 166, pp.675~682 (2009)
21. Goldberg TE, "Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?", Arch Gen Psychiatry, 64, pp.1115~1122 (2007)
22. Bilder RM, "Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder", Am J Psychiatry, 159, pp.1018~1028 (2002)
23. Keefe RS, "Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison", Am J Psychiatry, 164, pp.1061~1071 (2007)
24. Hoff AL, "The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients", Neuropsychopharmacology, 15, pp.361~369 (1996)
25. Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
26. Harvey PD, "Negative symptoms and cognitive deficits: what is the nature of their relationship?", Schizophr Bull, 32, pp.250~258 (2006)
27. Carpenter WT, "Another view of therapy for cognition in schizophrenia", Biol Psychiatry, 51, pp.969~971 (2002)
28. Harvey PD, "Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning", Am J Psychiatry, 163, pp.1918~1925 (2006)
29. Voruganti LP, "Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine", Schizophr Res, 96, pp.146~155 (2007)
30. Mohamed S, "Relationship of cognition and psychopathology to functional impairment in schizophrenia", Am J Psychiatry, 165, pp.978~987 (2008)
31. Marder SR, "Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia", Schizophr Res, 72, pp.5~9 (2004)
32. Green MF, "Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMHMATRICS conference to select cognitive domains and test criteria", Biol Psychiatry, 56, pp.301~307 (2004)
33. Weinberger DR, "Prefrontal function in schizophrenia: confounds and controversies", Philos Trans R Soc Lond B Biol Sci, 351, pp.1495~1503 (1996)
34. Keshavan MS, "Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology", Schizophr Res, 106, pp.89~107 (2008)
35. Lawrie SM, "Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk", Schizophr Bull, 34, pp.330~340 (2008)
36. McGuire P, "Functional neuroimaging in schizophrenia: diagnosis and drug discovery", Trends Pharmacol Sci, 29, pp.91~98 (2008)
37. Minzenberg MJ, "Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia", Arch Gen Psychiatry, 66, pp.811~822 (2009)
38. Honey GD, "Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia", Proc Natl Acad Sci USA, 96, pp.13432~13437 (1999)
39. Lahti AC, "Clozapine but not haloperidol Re- establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex", Neuropsychopharmacology, 29, pp.171~178 (2004)
40. Snitz BE, "Lateral and medial hypofrontality in firstepisode schizophrenia: functional activity in a medicationnaive state and effects of short-term atypical antipsychotic treatment", Am J Psychiatry, 162, pp.2322~2329 (2005)
41. Schotte A, "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding", Psychopharmacology (Berl), 124, pp.57~73 (1996)
42. Shapiro DA, "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology", Neuropsychopharmacology, 28, pp.1400~1411 (2003)
43. Leucht S, "Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials", Am J Psychiatry, 159, pp.180~190 (2002)
44. Kapur S, "Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis", Am J Psychiatry, 158, pp.360~369 (2001)
45. GTPγS binding study, "Eur J Pharmacol", 1998, 245~256
46. Chou YH, "Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study", Psychopharmacology (Berl), 166, pp.234~240 (2003)
47. Mamo D, "Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study", Am J Psychiatry, 164, pp.1411~1417 (2007)
48. Araneda R, "Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex", Neuroscience, 40, pp.399~412 (1991)
49. Moghaddam B, "Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study", J Neurochem, 54, pp.1755~1760 (1990)
50. VolontéM, "BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex", J Neurochem, 69, pp.182~190 (1997)
51. Kuroki T, "Effects of antipsychotic drugs on extracellular dopamine levels in rat prefrontal cortex and nucleus accumbens", J Pharmacol Exp Ther, 288, pp.774~781 (1999)
52. Youngren KD, "Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment", Neurosci Lett, 165, pp.41~44 (1994)
53. Yamamoto BK, "Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations", J Neurosci, 14, pp.4159~4166 (1994)
54. Youngren KD, "Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus", Neuropsychopharmacology, 20, pp.403~412 (1999)
55. Rollema H, "5-HT 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex", Biol Psychiatry, 48, pp.229~237 (2000)
56. Ichikawa J, "Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism", Brain Res, 956, pp.349~357 (2002)
57. Li Z, "Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain", Eur J Pharmacol, 493, pp.75~83 (2004)
58. Goldman-Rakic PS, "Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction", Psychopharmacology (Berl), 174, pp.3~16 (2004)
59. Zahrt J, "Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance", J Neurosci, 17, pp.8528~8535 (1997)
60. Ichikawa J, "DOI, a 5-HT2A", 2C receptor agonist, attenuates clozapine-induced cortical dopamine release, 2001, pp.907, 151~155
61. Ichikawa J, "5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release", J Neurochem, 76, pp.1521~1531 (2001)
62. Lié.geois JF, "5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner", Brain Res, 947, pp.157~165 (2002)
63. Dí.az-Mataix L, "Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action", J Neurosci, 25, pp.10831~10843 (2005)
64. Jordan S, "In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function", Eur J Pharmacol, 483, pp.45~53 (2004)
65. Bortolozzi A, "In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain", Psychopharmacology (Berl), 191, pp.745~758 (2007)
66. Del Arco A, "Dopamine release in the prefrontal cortex during stress is reduced by the local activation of glutamate receptors", Brain Res Bull, 56, pp.125~130 (2001)
67. Bleakman D, "Neuropharmacology of AMPA and kainate receptors", Neuropharmacology, 37, pp.1187~1204 (1998)
68. Bymaster FP, "Radioreceptor binding profile of the atypical antipsychotic olanzapine", Neuropsychopharmacology, 14, pp.87~96 (1996)
69. Michal P, "Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors", Eur J Pharmacol, 376, pp.119~125 (1999)
70. Gomeza J, "Enhancement of D1 dopamine receptormediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice", Proc Natl Acad Sci USA, 96, pp.10483~10488 (1999)
71. Shekhar A, "Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia", Am J Psychiatry, 165, pp.1033~1039 (2008)
72. Parada MA, "Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum", J Pharmacol Exp Ther, 281, pp.582~588 (1997)
73. Ichikawa J, "Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum", Neuropsychopharmacology, 26, pp.325~339 (2002)
74. Shirazi-Southall S, "Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat", Neuropsychopharmacology, 26, pp.583~594 (2002)
75. Ichikawa J, "5-HT1A and 5-HT2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex", Brain Res, 939, pp.34~42 (2002)
76. Sur C, "N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-Daspartate receptor activity", Proc Natl Acad Sci USA, 100, pp.13674~13679 (2003)
77. Natesan S, "Kapur S. Evaluation of N-desmethylclozapine as a potential antipsychotic-- preclinical studies", Neuropsychopharmacology, 32, pp.1540~1549 (2007)
78. Lameh J, "Pharmacology of N-desmethylclozapine", Pharmacol Ther, 115, pp.223~231 (2007)
79. Li Z, "N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors", Neuropsychopharmacology, 30, pp.1986~1995 (2005)
80. Burstein ES, "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2", D3 partial agonist, 2005, pp.315, 1278~1287
81. Onali P, "N-desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious deltaopioid agonist at recombinant and native receptors", Neuropsychopharmacology, 32, pp.773~785 (2007)
82. Weiner DM, "The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine", Psychopharmacology (Berl), 177, pp.207~216 (2004)
83. Sumiyoshi T, "Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study", Schizophr Res, 95, pp.158~168 (2007)
84. Goff DC, "A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia", Neuropsychopharmacology, 33, pp.465~472 (2008)

관련 논문AI추천